论文部分内容阅读
前列腺特异抗原(PSA)自1979年首次发现以来,作为一种特殊的生物学标志物,一直用于前列腺癌的治疗观察、随访和筛查。多年的研究一致认为 PSA>4.0ng/ml 是筛查前列腺癌(建议前列腺活检)的标准上限,但缺乏对PSA≤4.0ng/ml(尤其是 PSA<2.5ng/ml)人群中前列腺癌发病情况的有价值的研究。由美国癌症研究所(NCI)发起的前列腺癌预防试验中的安慰剂组人群,由于该研究结束时行前列腺活检,这为研究正常 PSA 范围(PSA≤4.0ng/ml)内前列腺癌的发病情况创造了机会。对象与方法前列腺癌预防试验是一项随机、双盲、
Prostate Specific Antigen (PSA) has been used as a specific biomarker for the treatment of prostate cancer, follow-up and screening since it was first discovered in 1979. Years of research have consistently agreed that PSA> 4.0 ng / ml is the standard upper limit for screening for prostate cancer (recommended for prostate biopsies) but lacks the risk for prostate cancer in those with PSA <4.0 ng / ml (especially PSA <2.5 ng / ml) Valuable research. The placebo population in the Prostate Cancer Prevention Trial sponsored by the U.S. Cancer Institute (NCI), which is a prospective study of prostatic cancer in the normal PSA range (PSA ≤ 4.0 ng / ml) due to prostate biopsy at the end of the study Create a chance. Subjects and Methods The Prostate Cancer Prevention Trial is a randomized, double-blind,